Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model.
OBJECTIVE
To determine the effect of intravitreal anakinra on choroidal neovascularization (CNV) in an animal model.


METHODS
Laser photocoagulation used to rupture Bruch's membrane; animals then assigned to groups based on varying frequency of intravitreal anakinra injections. At day 30, digital angiography was used to measure the CNV area.


RESULTS
Intravitreal anakinra dose-dependently inhibited CNV growth. Injections given one time resulted in a 26% reduction in CNV; in the once weekly group, a 41% reduction was seen; in the twice-weekly group, a 62% reduction was seen (all p < .001).


CONCLUSIONS
Suppressing IL-1 function may provide another therapeutic avenue in exudative AMD.
Olson
Jeffrey L
JL
University of Colorado Denver, Denver, Colorado, USA. Jeffrey.Olson@UCHSC.edu
Courtney
Robert J
RJ
Rouhani
Behnaz
B
Mandava
Naresh
N
Dinarello
Charles A
CA
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D003911:Dextrans; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005451:Fluorescein Angiography; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives; D007267:Injections; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D003911:Dextrans; D053590:Interleukin 1 Receptor Antagonist Protein; C015219:fluorescein isothiocyanate dextran; D016650:Fluorescein-5-isothiocyanate